Although the demonstration of the anti-tumor properties of this glucocorticoid have also been previously reported [45,46,47,48], the combination of NLRP3 inhibition and dexamethasone resulted in a marked reduction in tumor volume compared to either treatment alone. This evidence concerns the gene NLRP3 and neoplasm.